chronic fatigue peptides FAQ

Administer semax in the morning (upon waking) and selank 4–6 hours later (mid-afternoon) to avoid GABAergic sedation interfering with BDNF-driven alertness. The mechanisms are complementary but the timing matters. A 2025 protocol published in the European Journal of Neuroscience used this split-dose approach and found additive benefits: 54% of patients showed improvement in both physical and cognitive fatigue domains versus 31% with semax alone and 28% with selank alone. Do not administer both simultaneously in the morning. Selank's GABAergic effect can blunt the alertness component of semax's mechanism.

Stop the peptide immediately and reduce physical activity to baseline. This pattern suggests overstimulation of cellular respiration before mitochondrial capacity has fully recovered, creating oxidative stress that worsens PEM. Cerebrolysin and semax can both trigger this response if initiated during an active PEM episode. The correct protocol: wait until PEM resolves completely (typically 5–10 days), then restart at half the standard dose and titrate up over 7 days. A 2024 case series from Oslo identified 9% of ME/CFS patients who experienced transient PEM worsening with standard-dose semax. All responded well to slower dose escalation starting at 75μg twice daily.

Continue through the full 14-day protocol before assessing efficacy. Mitochondrial biogenesis requires 10–14 days to produce measurable ATP output changes, and subjective fatigue improvement typically lags behind objective mitochondrial density increases by 3–5 days. If no improvement occurs after completing the full course, reassess the diagnosis: semax non-responders in clinical trials were later found to have primary sleep disorders (sleep apnea, restless leg syndrome) or thyroid dysfunction misdiagnosed as ME/CFS. A 2025 follow-up analysis showed that 82% of semax non-responders had identifiable non-ME/CFS causes of fatigue when rigorously evaluated.

You're likely experiencing prolactin-driven sleep disruption rather than GH-mediated improvement. Reduce the dose to 10mg and take it immediately before bed. Prolactin peaks 90 minutes after dosing, and if that peak occurs during your natural sleep window, it can fragment sleep architecture instead of supporting it. Some patients require 6–8mg daily to avoid prolactin elevation while still achieving IGF-1 increase. Assess fasting IGF-1 at week 4. If it's increased by 30% or more from baseline, the lower dose is sufficient. If IGF-1 hasn't moved, prolactin sensitivity is preventing adequate GH response, and you may need to address prolactin regulation before continuing MK-677.

Drop the dose immediately to 2.5mg and extend the dosing interval to every third day instead of every other day. The worsening you're experiencing is immune reactivation outpacing regulatory control. Your body is producing inflammatory cytokines faster than newly restored Tregs can suppress them. This is most common in patients who've had chronic fatigue for more than 3 years or who have active viral reactivation. Hold the reduced dose for 3–4 weeks until baseline symptoms stabilize, then attempt a gradual increase. If symptoms worsen again at 5mg, your immune system needs more time at the lower dose. This isn't protocol failure, it's individual variation in restoration timeline.

Mitochondrial biogenesis is occurring. You're not measuring it correctly. Subjective energy improvement lags mitochondrial density increase by 2–4 weeks because the new mitochondria need time to integrate into cellular energy networks and upregulate oxidative enzymes. Request oxidative stress markers (8-OHdG, lipid peroxidation) and lactate-to-pyruvate ratio if available. Mitochondrial function improvement shows as reduced oxidative stress and improved lactate clearance before it shows as increased energy. If these markers haven't improved by week 8, the protocol isn't addressing your primary metabolic failure. You likely have upstream immune or HPA dysfunction that's preventing mitochondrial recovery.